Aspirin may reduce death In hospitalized COVID-19 patients

Researchers at the George Washington University published findings from the world's largest cohort study showing that hospitalized patients with moderate COVID-19 who were given aspirin early on in their treatment had a lower risk of dying compared to patients who were not given aspirin.

Lead researcher, Jonathan Chow said, "This is our third study and the culmination of 15 months of work looking at aspirin use in hospitalized COVID-19 patients. We continue to find that aspirin use is associated with improved outcomes and lower rates of death in hospitalized patients. What’s more, it’s low cost and readily available, which is important in parts of the world where more expensive therapeutics might not be as accessible."

The study included the largest data set of 112,269 patients hospitalized with moderate COVID-19. The data included patients enrolled from January 1, 2020, through September 10, 2021, at 64 health systems in the United States participating in the National Institute of Health's National COVID Cohort Collaborative (N3C).

Researchers found a 1.6% reduction in mortality when aspirin was given within the first day of hospitalization in patients with moderate disease severity and that patients were less prone to forming blood clots. They also found that elderly patients and patients with one or more comorbidities especially benefit from early aspirin therapy.

Keith Crandall, Director of the Computational Biology Institute (CBI) at George Washington University, the organization that helped assemble and input GW's data into the NIH database and curate the dataset into a usable format for the statistical analysis, said, "This research is vital to providing physicians and patients effective and accessible COVID-19 treatments to help reduce in-hospital mortality rates and help people recover from this potentially devastating disease."

Chow JH, Rahnavard A, Gomberg-Maitland M, et al.
Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19.
JAMA Netw Open. 2022;5(3):e223890. doi: 10.1001/jamanetworkopen.2022.3890

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...